EGFR and non-small cell lung carcinoma: In 2021, Amivantamab was approved by the US FDA for the treatment of patients with advanced or metastatic NSCLC with EGFR ex20-ins mutations, whose disease had progressed during or after platinum-based chemotherapy [127].